Gaudium IVF & Women Health IPO Details

MAINBOARD

Gaudium IVF & Women Health IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.

Offer for Sale consists of 25,31,700 shares (aggregating up to ₹0.00 Cr.). Pre-issue shareholding stands at 6,13,94,384, which will increase to 7,97,48,784 post-issue.

The Lead Managers for Gaudium IVF & Women Health IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Sarthi Capital Advisors Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For detailed information, Refer to the Gaudium IVF & Women Health Limited DRHP.

Gaudium IVF & Women Health IPO Details

Open Date
-
Close Date
-
Listing Date
-
Issue Price
₹0 - ₹0
Face Value
₹5 per share
Lot Size
0
GMP
₹0
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
6,13,94,384 shares
Share holding post issue
7,97,48,784 shares
Total Issue Size
-
Fresh Issue
-25,31,700 shares
Offer for Sale
25,31,700 shares (aggregating up to ₹0.00 Cr.)
DRHP Status
SEBI Approval Received

Gaudium IVF & Women Health IPO Lot Size

ApplicationLotsSharesAmount
To be announced

Gaudium IVF & Women Health IPO Reservation

Promoter Holding

Pre Issue:99.99%
Post Issue:73.80%
Promoter Names:
Dr. Manika Khanna, Dr.Peeyush Khanna, Vishad Khanna

Gaudium IVF & Women Health IPO Valuations

ROE:59.29%
ROCE:46.27%
DEBT/EQUITY:0.52
RONW:49.90%
PAT MARGIN:30.89%

Gaudium IVF & Women Health Financial Information

Period Ended30 Sep 202431 Mar 202431 Mar 202331 Mar 2022
Assets72.2757.2936.6317.77
Total Income31.753.7544.2636.52
Profit After Tax8.1416.613.528.83
Net Worth41.5533.2722.739.29
Total Borrowing19.4815.739.785.95
Amount in ₹ Crore

About Gaudium IVF & Women Health IPO

Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.

The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.

The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.

The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.

The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Our treatments are designed for various infertility challenges for both genders. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.

The facilities provide a comprehensive range of male infertility treatments, including advanced sperm retrieval techniques.
As of September 30, 2024, the company had 118 employees across its operations.
Competitive Strength
  • Patient-Centric Approach
  • Focus on healthcare for underprivileged communities
  • Using next-gen INTEGRA Ti labs for ICSI.
  • Highly Technical USG Guided Services
  • Established central hubs in prime urban locations, including Mumbai, Bangalore, Delhi NCR, and Patna.

Strength Of Gaudium IVF & Women Health IPO

To be announced

Risk Of Gaudium IVF & Women Health IPO

To be announced

Objectives Gaudium IVF & Women Health IPO

1. Funding capital expenditure towards establishment of New IVF Centers of the Company

2. Funding working capital requirements for the establishment of New IVF Centers

3. Investment in our Wholly Owned Subsidiary(WOS), EKK Global Private Limited for: a)Launching of FMCG products; and b)Funding its Working Capital Requirements

4. General Corporate Purpose

Company Contact Details

Gaudium IVF & Women Health Ltd.
B1/51,
Janak Puri,
B-1,
New Delhi, New Delhi, 110058
Phone: 011-4885 8585
Email: compliance@gaudiumivfcentre.com
Website: https://www.gaudiumivfcentre.com/

Registrar Contact Details

Name: Bigshare Services Pvt Ltd
Phone: +91-22-62638200

Gaudium IVF & Women Health IPO - FAQs

The Gaudium IVF & Women Health IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹5 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.

The IPO opens for subscription on TBA, and closes on TBA.

Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

The Gaudium IVF & Women Health IPO opens on TBA.

Gaudium IVF & Women Health IPO lot size is 0, and the minimum amount required for application is ₹0.

You may apply for the Gaudium IVF & Women Health IPO online by using either the UPI or ASBA payment method. The ASBA facility is available through the net banking platform of your respective bank. The UPI-based IPO application option is typically provided by brokers that do not offer banking services. For detailed guidance on the online IPO application process, please refer to the procedures outlined by Zerodha, Groww, Upstox, 5Paisa, Paytm Money, Fyers, Alice Blue, Nuvama, HDFC Bank, ICICI Direct, Kotak Securities, Axis Direct, and SBI Bank.

The Basis of Allotment for the Gaudium IVF & Women Health IPO is scheduled to be finalized on TBA. Subsequently, the shares allotted will be credited to investors’ demat accounts by TBA. Investors are advised to regularly check the Gaudium IVF & Women Health IPO allotment status for updates.

The listing date for the Gaudium IVF & Women Health IPO has not yet been officially announced. However, the tentative listing date is scheduled for TBA.

Gaudium IVF & Women Health IPO Grey Market Premium (GMP) refers to the unofficial price at which the company’s IPO shares are traded in the grey market prior to their listing on the stock exchange. The GMP serves as an indicator of investor demand, expected listing gains, and the overall market sentiment toward the IPO.

As of now, the current GMP stands at TBA.

Comments